Evaj Pell News Today

Climate scientist Michael Mann has sued the Competitive Enterprise Institute and the National Review for defamation over statements that accuse Mann of scientific misconduct and that compare him to convicted child molester Jerry Sandusky.

Local news from StateCollege.com and Centre County Partners. Read about Local Author to Speak on Her Journey from Scientist to Author and more from the State College, PA region

STATE COLLEGE — The Nittany Valley Writers Network will meet on Tuesday, April 9, at 6:30 p.m., in the Schlow Library Community Room, 211 S. Allen St., State

STATE COLLEGE — The Nittany Valley Writers Network will meet at 6:30 p.m. Tuesday, April 9, in the Schlow Library Community Room, 211 S. Allen St., State College.

Nittany Writers to host author STATE COLLEGE — The Nittany Valley Writers Network will meet at 6:30 p.m. Tuesday, April 9, in the Schlow Library Community Room, 211 S. Allen St., State College. Guest speaker, Eva J. Pell, will discuss “My Unlikely Journey — From Scientist to Children’s Author; From Idea to Publication.” Pell began […]

First step toward understanding monkeypox's ability to replicate in the respiratory cells of cattle and pigs in a controlled in vitro environment.

Penn State researchers will study the monkeypox virus to understand the potential for it to spill over from humans to animals, as well as its pathogenesis — or disease development — in animal and human cells in vitro. In addition, they will study potential targets for therapeutics to treat the monkeypox disease.

This year’s Children’s Corner at the Literary Hill BookFest promises to be the best yet! Capitol Hill schoolteacher Nicole Siegel is coordinating a day of activities guaranteed to delight youngst

Several FDA-approved drugs — including for type 2 diabetes, hepatitis C and HIV — significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically

Several FDA-approved drugs — including for type 2 diabetes, hepatitis C and HIV — significantly reduce the ability of the Delta variant of SARS-CoV-2 to